logo
AAT Bioquest

HLA class II histocompatibility antigen DRB3-1 Inhibitors (IC50, Ki)

Structure
Compound Name
Standard Type
Standard Values (in nM)
(3S)-3-[[(2S)-1-[(2S)-6-Amino-2-[[(3S)-3-cyclohexylbutanoyl]amino]hexanoyl]piperidine-2-carbonyl]amino]-4-[(2S)-2-[[(2S,3R)-3-hydroxy-1-oxo-1-(propylamino)butan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxobutanoic acidIC50100.0 [1]
(3S)-3-[[(2S)-1-[(2S)-2-(3-Cyclohexylpropanoylamino)-3-methylbutanoyl]piperidine-2-carbonyl]amino]-4-[(2S)-2-[[(2S,3R)-3-hydroxy-1-oxo-1-(propylamino)butan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxobutanoic acidIC50130.0 [1]
(3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-Acetamido-3-naphthalen-1-ylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]-4-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acidIC5031.0 [1]
(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-Acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanamideIC50180.0 [1]
3-[[1-[(2S)-2-[[(3R)-3-Cyclohexylbutanoyl]amino]-3-methylbutanoyl]piperidine-2-carbonyl]amino]propanoic acidIC50100000.0 [1]
(3S)-3-[[1-[(2S)-2-[[(3R)-3-Cyclohexylbutanoyl]amino]-6-(decanoylamino)hexanoyl]piperidine-2-carbonyl]amino]-4-[(2S)-2-[[(2S,3R)-3-hydroxy-1-oxo-1-(propylamino)butan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxobutanoic acidIC5010000.0 [1]
(3S)-3-[[2-[(2S)-6-Amino-2-[[(3S)-3-cyclohexylbutanoyl]amino]hexanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]amino]-4-[(2S)-2-[[(2S,3R)-3-hydroxy-1-oxo-1-(propylamino)butan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxobutanoic acidIC50303.0 [1]
(3S)-3-[[(2S)-2-[[(2S)-6-Amino-2-[[(3S)-3-cyclohexylbutanoyl]amino]hexanoyl]-methylamino]propanoyl]amino]-4-[(2S)-2-[[(2S,3R)-3-hydroxy-1-oxo-1-(propylamino)butan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxobutanoic acidIC501800.0 [1]
(3S)-3-[[(2S)-1-[(2S)-6-Amino-2-[[(3S)-3-cyclohexylbutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-4-[(2S)-2-[[(2S,3R)-3-hydroxy-1-oxo-1-(propylamino)butan-2-yl]carbamoyl]piperidin-1-yl]-4-oxobutanoic acidIC5016000.0 [1]
(3S)-3-[[(2S)-1-[(2S)-6-Amino-2-[[(3S)-3-cyclohexylbutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-4-[(2S)-2-[[(2S,3R)-3-hydroxy-1-oxo-1-(propylamino)butan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxobutanoic acidIC502500.0 [1]
(2S)-1-[(2S)-2-(3-Cyclohexylpropanoylamino)-3-(1H-imidazol-5-yl)propanoyl]-N-[(2S)-1-[(2S)-2-[[(2S,3R)-3-hydroxy-1-(3-methylbutylamino)-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]piperidine-2-carboxamideIC50100000.0 [1]
(3S)-3-[[(2S)-1-[(2S)-2-[[(3S)-3-Cyclohexylbutanoyl]amino]-2-phenylacetyl]piperidine-2-carbonyl]amino]-4-[(2S)-2-[[(2S,3R)-3-hydroxy-1-oxo-1-(propylamino)butan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxobutanoic acidIC50424.0 [1]
(3S)-3-[[(2S)-1-[(2S)-2-Cyclohexyl-2-[[(3S)-3-cyclohexylbutanoyl]amino]acetyl]piperidine-2-carbonyl]amino]-4-[(2S)-2-[[(2S,3R)-3-hydroxy-1-oxo-1-(propylamino)butan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxobutanoic acidIC50170.0 [1]
(2S)-1-[(2S)-2-[[2-(Cyclohexylamino)acetyl]amino]-3-methylbutanoyl]-N-[(2S)-1-[(2S)-2-[[(2S,3R)-3-hydroxy-1-oxo-1-(propylamino)butan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-methylsulfanyl-1-oxobutan-2-yl]piperidine-2-carboxamideIC50100000.0 [1]
(3S)-4-[(2S)-2-Carbamoylpyrrolidin-1-yl]-3-[[(2S)-1-[(2S)-2-[[(3S)-3-cyclohexylbutanoyl]amino]-3-methylbutanoyl]piperidine-2-carbonyl]amino]-4-oxobutanoic acidIC5023300.0 [1]
(3S)-3-[[(2S)-1-[(2S,3R)-2-[[(3S)-3-Cyclohexylbutanoyl]amino]-3-hydroxybutanoyl]piperidine-2-carbonyl]amino]-4-[(2S)-2-[[(2S,3R)-3-hydroxy-1-oxo-1-(propylamino)butan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxobutanoic acidIC501300.0 [1]
(3S)-3-[[(2S)-1-[(2S)-2-[[(3S)-3-Cyclohexylbutanoyl]amino]-3-methylbutanoyl]piperidine-2-carbonyl]amino]-4-[(2S)-2-[[(2R,3R)-1,3-dihydroxybutan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxobutanoic acidIC507000.0 [1]
(3S)-3-[[(2S)-1-[(2S)-6-Amino-2-(4-cyclohexylheptanoylamino)hexanoyl]piperidine-2-carbonyl]amino]-4-[(2S)-2-[[(2S,3R)-3-hydroxy-1-oxo-1-(propylamino)butan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxobutanoic acidIC50100000.0 [1]
(3S)-3-[[(2S)-1-[(2S)-2-(3-Cyclohexylpropanoylamino)-3-(1H-imidazol-5-yl)propanoyl]piperidine-2-carbonyl]amino]-4-[(2S)-2-[[(2S,3R)-3-hydroxy-1-(3-methylbutylamino)-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxobutanoic acidIC503150.0 [1]
(2S)-1-[(2S)-2-[[(3S)-3-Cyclohexylbutanoyl]amino]-3-methylbutanoyl]-N-[(2S)-1-[(2S)-2-[[(2S,3R)-3-hydroxy-1-oxo-1-(propylamino)butan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-methylsulfanyl-1-oxobutan-2-yl]piperidine-2-carboxamideIC50293.0 [1]
(2S)-1-[(2S)-2-[[(3S)-3-Cyclohexylbutanoyl]amino]-3-methylbutanoyl]-N-[(2S)-1-[(2S)-2-[[(2S,3R)-3-hydroxy-1-oxo-1-(propylamino)butan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopent-4-yn-2-yl]piperidine-2-carboxamideIC5043700.0 [1]
(3S)-4-[(2S)-2-[[(2S)-3-Amino-1-oxo-1-(propylamino)propan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-[[(2S)-1-[(2S)-2-[[(3S)-3-cyclohexylbutanoyl]amino]-3-methylbutanoyl]piperidine-2-carbonyl]amino]-4-oxobutanoic acidIC50100000.0 [1]
(3S)-3-[[(2S)-1-[(2S)-6-Amino-2-[[(3R)-3-cyclohexylbutanoyl]amino]hexanoyl]piperidine-2-carbonyl]amino]-4-[(2S)-2-[[(2S,3R)-3-hydroxy-1-oxo-1-(propylamino)butan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxobutanoic acidIC50162.0 [1]
(3S)-3-[[(2S)-1-[(2S)-6-Amino-2-[3-(2-bicyclo[2.2.1]heptanyl)propanoylamino]hexanoyl]piperidine-2-carbonyl]amino]-4-[(2S)-2-[[(2S,3R)-3-hydroxy-1-oxo-1-(propylamino)butan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxobutanoic acidIC5076.0 [1]
(3S)-3-[[(2S)-1-[(2S)-6-Amino-2-(3-cycloheptylpropanoylamino)hexanoyl]piperidine-2-carbonyl]amino]-4-[(2S)-2-[[(2S,3R)-3-hydroxy-1-oxo-1-(propylamino)butan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxobutanoic acidIC50178.0 [1]
(3S)-3-[[(2S)-1-[(2S)-2-[[(3S)-3-Cyclohexylbutanoyl]amino]-3-methylbutanoyl]piperidine-2-carbonyl]amino]-4-[(2S)-2-[[(2S,3R)-3-hydroxy-1-oxo-1-(propylamino)butan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxobutanoic acidIC5050.0 [1]



References

This online tool may be cited as follows

MLA

"Quest Database™ HLA class II histocompatibility antigen DRB3-1 Inhibitors (IC50, Ki)." AAT Bioquest, Inc.21 Nov2024https://www.aatbio.com/data-sets/hla-class-ii-histocompatibility-antigen-drb3-1-inhibitors-ic50-ki.

APA

AAT Bioquest, Inc. (2024November 21). Quest Database™ HLA class II histocompatibility antigen DRB3-1 Inhibitors (IC50, Ki). AAT Bioquest. https://www.aatbio.com/data-sets/hla-class-ii-histocompatibility-antigen-drb3-1-inhibitors-ic50-ki.
BibTeXEndNoteRefMan